Citation Impact
Citing Papers
OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
2012 Standout
Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study
2003 Standout
Tumour-cell invasion and migration: diversity and escape mechanisms
2003 Standout
Guideline for disinfection and sterilization in healthcare facilities, 2008
2008 Standout
Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data
1997 Standout
Accumulation of 99mTc-low-density lipoprotein in human malignant glioma
1995
Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis
2002 Standout
Use of mass media campaigns to change health behaviour
2010 Standout
Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial
2015 Standout
Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer
1999 Standout
Preoperative Determination of Several Serum Tumor Markers in Patients with Primary Epithelial Ovarian Carcinoma
1999
Management of ovarian cancer: referral to a multidisciplinary team matters
1994
Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer
1997 Standout
HIF-1α, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas
2005 StandoutNobel
Cisplatin, Radiation, and Adjuvant Hysterectomy Compared with Radiation and Adjuvant Hysterectomy for Bulky Stage IB Cervical Carcinoma
1999 Standout
Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.
1991 Standout
A meta-analysis of prognostic factors in advanced ovarian cancer with median survival and overall survival (measured with the log (relative risk)) as main objectives
1989
Objective structured assessment of technical skill (OSATS) for surgical residents
1997 Standout
Surgical Skill and Complication Rates after Bariatric Surgery
2013 Standout
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
2003 Standout
The prediction of progression‐free and overall survival in women with an advanced stage of epithelial ovarian carcinoma
2009
Ovarian cancer
2014 Standout
Drug penetration in solid tumours
2006 Standout
β1-Integrins Partly Mediate Binding of Ovarian Cancer Cells to Peritoneal Mesothelium in Vitro
1999
Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer
1996 Standout
Influence of oral contraceptives in the development of post-molar trophoblastic neoplasia—A systematic review
2005
Gestational trophoblastic disease
2010 Standout
Metabolism and action of amino acid analog anti-cancer agents
1990
An Expanded Set of Amino Acid Analogs for the Ribosomal Translation of Unnatural Peptides
2007 StandoutNobel
HSP90 and the chaperoning of cancer
2005 Standout
A randomised study of carboplatin vs sequential ifosfamide/carboplatin for patients with FIGO stage III epithelial ovarian carcinoma
1993
Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian Cancer
1996 Standout
Extraperitoneal versus transperitoneal selective paraaortic lymphadenectomy in the pretreatment surgical staging of advanced cervical carcinoma (A Gynecologic Oncology Group study)
1989
Aggressive multimodality treatment for cervical cancer with paraaortic lymph node metastases
1991
Social Relationships and Mortality Risk: A Meta-analytic Review
2010 Standout
Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy
2008 Standout
Topotecan in Platinum- and Paclitaxel-Resistant Ovarian Cancer
1997
Primary surgery for ovarian cancer
2006
In Vivo Spectral Fluorescence Imaging of Submillimeter Peritoneal Cancer Implants Using a Lectin-Targeted Optical Agent
2006
Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study.
1995
Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement
1999 Standout
Advanced epithelial ovarian carcinoma: Long-term survival experience at the community hospital
1992
Publication bias in clinical research
1991 Standout
Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study.
1989
Cervical Intraepithelial Neoplasia (Dysplasia and Carcinoma in Situ) And Early Invasive Cervical Carcinoma
1989
Teaching Surgical Skills — Changes in the Wind
2006 Standout
Pain and Its Treatment in Outpatients with Metastatic Cancer
1994 Standout
Assessment of technical skills transfer from the bench training model to the human model
1999
Correlation of the survival of ovarian cancer patients with mRNA expression of the 60-kD heat-shock protein HSP-60.
1993
Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma.
1989
Comparative toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer
1988
Social relations, social support and survival among patients with cancer
1992
Family planning: the unfinished agenda
2006
Ferroptosis: mechanisms, biology and role in disease
2021 Standout
Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma.
1996
Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas
1997
Structural and physico-chemical determinants of the interactions of macrocyclic photosensitizers with cells
2007
Surgical results of pelvic exenteration in the treatment of gynecologic cancer
2014
Cervical cancer
2019 Standout
The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume Stage III epithelial ovarian cancer: A gynecologic oncology group study
1992
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
2010 Standout
Ovarian cancer: Epidemiology, biology, and prognostic factors
2000
Carboplatin alone compared with its combination with epirubicin and cyclophosphamide in untreated advanced epithelial ovarian cancer: a hellenic co-operative oncology group study
1996
Cancer of the Ovary
2004 Standout
What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?
2006
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
The impact of pain on the patient with cancer
1984
Binding of Ovarian Cancer Antigen CA125/MUC16 to Mesothelin Mediates Cell Adhesion
2004 Standout
Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: Initial and long term results—Eastern Cooperative Oncology Group study E2878
1996
A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study.
1985
Prognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study
2007
New Strategies for Fluorescent Probe Design in Medical Diagnostic Imaging
2009 Standout
Clinical characteristics of clear cell carcinoma of the ovary
2000
Objective structured assessment of technical skill (OSATS) for surgical residents
1997 Standout
Matrix Metalloproteinases As Novel Biomarker s and Potential Therapeutic Targets in Human Cancer
2009
Cis-diamminedichloroplatinum II based combination chemotherapy for the control of extensive paraaortic lymph node metastasis in cervical cancer
1987
Intraepithelial CD8+tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
2005 Standout
Phase III Randomized Study of Cisplatin Versus Paclitaxel Versus Cisplatin and Paclitaxel in Patients With Suboptimal Stage III or IV Ovarian Cancer: A Gynecologic Oncology Group Study
2000
Confronting publication bias: A cohort design for meta‐analysis
1987
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial
2003 Standout
Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan
2001 Standout
Clinical studies with adjunctive surgery and irradiation therapy in the treatment of carcinoma of the cervix
1976
Multistage nanoparticle delivery system for deep penetration into tumor tissue
2011 StandoutNobel
Cisplatin combination chemotherapy versus chlorambucil in advanced ovarian carcinoma: mature results of a randomized trial.
1985
mice: Multivariate Imputation by Chained Equations inR
2011 Standout
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
2006 Standout
Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma
1999 Standout
The Chemistry of Neutron Capture Therapy
1998 Standout
Imaging and Photodynamic Therapy: Mechanisms, Monitoring, and Optimization
2010 Standout
Meta-analysis of the role of platinum compounds in advanced ovarian carcinoma. The Advanced Ovarian Cancer Trialists Group.
1992
Pre-treatment surgical para-aortic lymph node assessment in locally advanced cervical cancer
2013
Aspects of cytotoxic drug penetration, with particular reference to anthracyclines
1987
Enzymatic aminoacylation of tRNA with unnatural amino acids
2006 StandoutNobel
Publication bias: the case for an international registry of clinical trials.
1986
Factors Influencing Publication of Research Results
1992 Standout
Therapeutic implications of patterns of recurrence in cancer of the uterine cervix
1979
Actual Causes of Death in the United States
1993 Standout
A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A gynecologic oncology group study
1986
Prognostic factors in malignant epithelial ovarian tumors
1983
Works of Herbert J. Buchsbaum being referenced
Subarachnoid phenol block for pain relief in gynecologic malignancy.
1976
Psychosocial adjustment to pelvic exenteration
1975
Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience.
1991
Para-aortic lymph node irradiation in carcinoma of the cervix after exploratory laparotomy and biopsy-proven positive aortic nodes
1982
The canine laboratory in the training of the oncology fellow
1986
Bacteriuria in closed bladder drainage versus continuous irrigation in patients undergoing intracavitary radium for treatment of gynecologic cancer
1982
Experience with peritoneal cytology in the management of gynecologic malignancies
1974
Para-aortic lymph node involvement in cervical carcinoma
1972
Pelvic exenteration for vulvovaginal carcinoma
1981
Prophylactic chemotherapy in stages I and II uterine sarcoma
1979
Low-density lipoprotein as a potential vehicle for chemotherapeutic agents and radionucleotides in the management of gynecologic neoplasms
1981
Para-aortic lymph node irradiation in carcinoma of the uterine cervix
1974
Surgical Staging of Carcinoma of the Ovaries
1990
Failure of contraceptive steroids to modify human chorionic gonadotrophin secretion by hydatidiform mole tissue and choriocarcinoma cells in culture
1981
Extrapelvic lymph node metastases in cervical carcinoma
1979
Phase II trial of acivivin in patients with advanced epithelial ovarian carcinoma
1986
A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus adriamycin plus cyclophosphamide in ovarian carcinoma
1983